Investing in Boston Scientific Corporation (BSX)  ➔  Intrinsic value

Prev. close$43.71 
ModelValueUpside
Chepakovich$1.82-96%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$43.71  
Valuation MethodValuePotential 
Chepakovich Model$1.82-96%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Articles

Boston Scientific will get out of the pandemic with dignity

2020-05-12   Author: Stock Analyst   Category: Stock analysis

Thanks to an aggressive acquisition policy, the company has significantly expanded its product line, which has become highly diversified. We continue to view Boston Scientific shares as a promising investment for the coming year and recommend buying them with a target level of $42.   [read all]

Latest news

Company description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.